Angiotensin II activates extracellular signal-regulated kinase independently of receptor tyrosine kinases in renal smooth muscle cells: implications for blood pressure regulation
Autor: | Crisanto S. Escano, Alexander A. Gutweiler, Lindsay B Keever, Bradley T. Andresen |
---|---|
Rok vydání: | 2007 |
Předmět: |
MAPK/ERK pathway
medicine.medical_specialty Angiotensin receptor Myosin light-chain kinase Myocytes Smooth Muscle Aorta Thoracic Blood Pressure Mitogen-activated protein kinase kinase Kidney Rats Inbred WKY Internal medicine medicine Animals Vasoconstrictor Agents Receptors Platelet-Derived Growth Factor Extracellular Signal-Regulated MAP Kinases Cells Cultured Pharmacology Flavonoids Platelet-Derived Growth Factor Angiotensin II receptor type 1 biology Epidermal Growth Factor MEK inhibitor Angiotensin II Receptor Protein-Tyrosine Kinases Angiotensin-converting enzyme Tyrphostins Rats Endocrinology Calcium-Calmodulin-Dependent Protein Kinases biology.protein Quinazolines Molecular Medicine Protein Tyrosine Phosphatases |
Zdroj: | The Journal of pharmacology and experimental therapeutics. 324(1) |
ISSN: | 1521-0103 |
Popis: | Angiotensin II can cause hypertension through enhanced vasoconstriction of renal vasculature. One proposed mechanism for reduction of angiotensin II-induced hypertension is through inhibition of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase cascade. MEK/ERK has been shown to phosphorylate the regulatory subunit of myosin light chain at identical positions as myosin light chain kinase. There are multiple mechanisms proposed regarding angiotensin II-mediated ERK activation. We hypothesized that renal microvascular smooth muscle cells (RμVSMCs) signal through a unique pathway compared with thoracic aorta smooth muscle cells (TASMCs), which is involved in blood pressure regulation. Use of epidermal growth factor (EGF) and platelet derived growth factor (PDGF) receptor-specific inhibitors 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (AG1478) and 6,7-dimethoxy-3-phenylquinoxaline (AG1296), respectively, demonstrates that angiotensin II activates ERK in TASMCs, but not RμVSMCs, through transactivation of EGF and PDGF receptors. In addition, inhibition of Src with its specific inhibitor 4-amino-5-(4-chlorophenyl)-7-( t -butyl) pyrazolo[3,4- d ]pyrimidine (PP2) abolishes angiotensin II-, but not EGF-or PDGF-, mediated phosphorylation of ERK in RμVSMCs, yet it has no effect in TASMCs. The physiological significance of transactivation was examined in vivo using anesthetized Wistar-Kyoto rats with 15 mg/kg 2′-amino-3′-methoxyflavone (PD98059), an MEK inhibitor, as well as 20 mg/kg AG1478 and 1.5 mg/kg AG1296 in an acute model of angiotensin II-mediated increase in blood pressure. None of the inhibitors had an effect on basal blood pressure, and only PD98059 reduced angiotensin II-mediated increase in blood pressure. Moreover, in RμVSMCs, but not TASMCs, angiotensin II localizes phosphorylated ERK to actin filaments. In conclusion, angiotensin II signals through a unique mechanism in the renal vascular bed that may contribute to hypertension. |
Databáze: | OpenAIRE |
Externí odkaz: |